Canal Clinton E
Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA, USA.
Handb Exp Pharmacol. 2018;252:227-260. doi: 10.1007/164_2018_107.
Recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. Additionally, fresh results from a deluge of clinical neuroimaging studies are unveiling the dynamic effects of serotonergic psychedelics on functional activity within, and connectivity across, discrete neural systems. These observations have led to testable hypotheses regarding neural processing mechanisms that contribute to psychedelic effects and therapeutic benefits. Despite these advances and a plethora of preclinical and clinical observations supporting a central role for brain serotonin 5-HT receptors in producing serotonergic psychedelic effects, lingering and new questions about mechanisms abound. These chiefly pertain to molecular neuropharmacology. This chapter is devoted to illuminating and discussing such questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new.
近期,尽管规模较小但控制良好的临床试验表明,包括裸盖菇素和麦角酸二乙酰胺在内的血清素能迷幻剂在治疗包括难治性抑郁症在内的精神疾病方面具有巨大潜力。此外,大量临床神经影像学研究的新结果正在揭示血清素能迷幻剂对离散神经系统内功能活动以及跨系统连接的动态影响。这些观察结果引发了关于导致迷幻效果和治疗益处的神经处理机制的可测试假设。尽管有这些进展以及大量临床前和临床观察结果支持大脑5-羟色胺(5-HT)受体在产生血清素能迷幻效果中起核心作用,但关于机制的旧问题和新问题仍然大量存在。这些问题主要涉及分子神经药理学。本章致力于在研究血清素能迷幻剂作用机制的临床前实验方法(经典方法和新方法)的背景下阐明和讨论此类问题。